Health & BiotechClinical trials

Helus reports depression benefit for experimental psychedelic drug in Phase 3

“HLP003 was tested alongside existing antidepressants; the company also reported three treatment-related serious adverse events.”

How this story was made

This story was written with AI assistance from SEC EDGAR’s SEC filing. Its figures and quotations were checked against their sources, and Digitalage Desk reviewed and approved it before publication. It is published under the name of Peter Michaels, Editor.

Not investment advice.

AI-generated illustration of a ceramic bust in profile seen through a round magnifying lens
AI-generated illustration

Helus Pharma said Monday that its experimental drug HLP003 improved depression symptoms more than placebo in a Phase 3 trial involving people whose existing antidepressants had provided inadequate relief.

The November 16 results announcement also reported three treatment-related serious adverse events. It did not identify the events or say how many participants experienced them.

HLP003, a psychedelic-derived compound previously called CYB003, remains investigational and is not approved for sale.

What the trial tested

The APPROACH study examined whether adding HLP003 could help adults with moderate-to-severe major depressive disorder who were still experiencing symptoms on medication.

According to Helus’s trial description, participants continued their stable antidepressant treatment. They were randomly assigned to two oral doses of HLP003, three weeks apart, or inactive placebo. That design tests the added benefit of the experimental treatment; it does not establish how HLP003 compares directly with another antidepressant.

The reported analysis included 222 participants. Six weeks after the first dose, depression scores had fallen by an adjusted average of 19.5 points with HLP003 and 11.9 points with placebo. The 7.6-point difference was statistically significant, Helus said.

The measure, the Montgomery-Asberg Depression Rating Scale, tracks symptom severity. Lower scores indicate improvement; the figures are changes in scale points, not percentages of patients who recovered. Helus reported a seven-point advantage over placebo at 12 weeks.

Safety and the limits of the initial results

Helus described most adverse events as mild or moderate, short-lived and concentrated on dosing day.

Primary sourceSEC EDGAR: “Helus Pharma Form 8-K, Exhibit 99.1: APPROACH Phase 3 topline results”

That last question matters in psychedelic research. The FDA’s July 2026 guidance explains that noticeable drug effects can let participants or observers guess who received active treatment, potentially influencing expectations and symptom assessments.

Helus says its program uses remote, independent raters who are blinded to treatment assignment and kept uninformed about participants’ dosing experiences. Those are safeguards described by the company; the results release did not report a quantitative assessment of whether masking worked. The FDA guidance is general and does not judge this trial.

The agency also recommends follow-up beyond 12 weeks to examine symptom recurrence and repeat dosing. Helus’s ongoing EXTEND study is investigating longer-term outcomes. EMBRACE, its second pivotal trial, is ongoing, with results expected in the fourth quarter of 2027, the company said.

End of story